Firm Wire items are announcements made by the firms themselves. The desk confirms that the announcement was published and reproduces its factual content. It does not verify the claims in it, and publication is not an endorsement.
Cooley says it advised TriGemX Bio on its planned combination with TCGX
Cooley said it advised TriGemX Bio on its planned business combination with TCGX Acquisition Corp. The firm said the transaction would support development of elismetrep, TriGemX’s migraine treatment candidate, including work toward clinical trials, regulatory submissions and preparations for a potential United States launch.
Key points
- Cooley said the proceeds were expected to support a Phase 3 trial for acute migraine treatment.Cooley
- The firm said the plans included a new drug application for that indication.Cooley
- Cooley said development also included a migraine-prevention trial using a different dose and formulation.Cooley
- The firm said Div Gupta, Bill Sorabella, Eric Blanchard, Julia Kim and Susan Choy led its team.Cooley